Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April July May June August September October November December
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

ANC Centenary Dialogue reflects on past leadership
2011-10-12

 

Making their mark at the ANC Centenary Dialogue were, from left to right: Prof. Kwandiwe Kondlo, Senior Professor: Centre for Africa Studies (UFS); Dr Adekeye Adebajo, Director: Centre for Conflict Resolution (Cape Town); and Prof.  E C Ejiogu, Senior Researcher: Centre for Africa Studies (UFS). 

The Centre for Africa Studies at our university recently hosted its ANC Centenary Dialogue at the Bloemfontein Campus. Keynote speaker, Dr Adekeye Adebajo, delivered a paper titled Nelson Mandela, Thabo Mbeki, and the ANC’s Footprint in Africa. The lecture focused on two of South Africa’s democratically-elected presidents.

Mr Nelson Mandela was South Africa’s first democratically-elected president. This Nobel Peace Laureate played a prophetic leadership role in Africa in 1993. He was inspired by Mr Mahatma Gandhi’s tactics of ‘passive resistance’, which played a role in the ANC’s Defiance Campaign.
 
Mr Mandela’s visit to other African countries gave him insights into continental diplomacy and the tactics of other liberation movements. “The ANC used Madiba to embody the face of the struggle. He emerged from prison without any bitterness towards his enemies. He tirelessly promoted national reconciliation,” said Dr Adebajo.
 
Unlike other post-independence ‘Founding Fathers’, Mr Mandela bowed out gracefully at the end of his first presidential term in 1999, setting a standard for future African leaders aspiring to greatness. “Mr Mandela’s lasting legacies are his efforts at promoting national and international peacemaking,” elaborated Dr Adebajo.
 
Mr Thabo Mbeki challenged Africans to discover a sense of their own self-confidence after centuries of slavery and colonialism. Under his foreign policy, South Africa established solid credentials to become Africa’s leading power. He sought multilateral solutions to resolve regional conflicts. Mr Mbeki also sent peacekeepers abroad and increased South Africa’s credibility as a major geostrategic player in Africa.
 
Many question whether Mr Mbeki’s heirs, President Jacob Zuma and beyond, will maintain the same level of commitment to the continent that he demonstrated. Mr Mbeki has bequeathed this foreign policy legacy to his successors. “These very different ANC leaders have left a heavy African footprint on the sands of time,” concluded Dr Adebajo.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept